Non-Cystic Fibrosis Bronchiectasis (NCFB) - Epidemiology Forecast - 2034
Description
Key Highlights
NCFB is a chronic lung condition marked by permanent bronchial dilation, leading to persistent sputum production, impaired bacterial clearance, and a cycle of infections, inflammation, and lung damage. Common symptoms include cough, sputum, and recurrent respiratory infections.
NCFB is frequently accompanied by comorbidities like anxiety, depression, and fatigue.
The causes of NCFB are varied, with many cases associated with idiopathic factors, post-infective causes, Chronic Obstructive Pulmonary Disease (COPD), asthma, and other conditions.
In 2024, there were approximately 1,050,000 diagnosed prevalent cases of NCFB in the 7MM.
Among the 7MM, the US accounted for approximately 37%, EU4 and the UK for nearly 54%, and Japan for around 9% of the total diagnosed prevalent cases of NCFB in 2024.
In 2024, females made up approximately 60% of diagnosed prevalent NCFB cases in the 7MM, while males accounted for around 40%.
DelveInsight’s “Non-cystic Fibrosis Bronchiectasis (NCFB) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of NCFB, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Non-cystic Fibrosis Bronchiectasis (NCFB): Disease Understanding
Non-cystic Fibrosis Bronchiectasis (NCFB) Overview, and Diagnosis
NCFB is a chronic respiratory condition involving irreversible bronchial dilation caused by airway injury, leading to inflammation, excess mucus production, and recurrent infections. NCFB, once under recognized and classified as an orphan respiratory disease, has become more prevalent globally, partly due to increased access to chest CT imaging.
Symptoms of NCFB range from occasional respiratory infections with excess mucus to chronic daily production of purulent sputum. Although not clearly defined, exacerbations typically involve increased sputum, worsening cough, wheezing, shortness of breath, hemoptysis, and declining lung function.
Diagnosis is primarily based on chest CT scans, though additional tests such as chest X-rays, bronchoscopy, pulmonary function tests, blood work, and sputum cultures may be conducted to detect underlying causes.
Non-cystic Fibrosis Bronchiectasis (NCFB) Epidemiology
The NCFB epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases, severity-specific diagnosed prevalent cases, gender-specific diagnosed prevalent cases, etiology-specific diagnosed prevalent cases, and microbiology of NCFB patients, in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.
In 2024, the total diagnosed prevalent cases of NCFB was approximately 388,000 in the US.
Among EU4 and the UK, the UK had the highest diagnosed prevalent population of NCFB, with nearly 229,500 cases in 2024, followed by Spain with approximately 152,200 cases. On the other hand, France had the lowest diagnosed prevalent population, with approximately 38,300 cases.
In 2024, there were approximately 90,000 mild, 160,000 moderate, and 138,000 severe cases of NCFB in the US.
In 2024, out of the diagnosed prevalent NCFB cases in US, ~105,000 were infected with P. aeruginosa, ~89,000 with H. influenzae, ~31,000 with S. pneumoniae, and ~78,000 with other pathogens, while no pathogenic growth was detected in ~85,000 cases.
In 2024, the gender-specific diagnosed prevalent cases of NCFB in the US were approximately 34% in males and 66% in females.
Scope of the Report
The report covers a segment of an executive summary, and a descriptive overview NCFB explaining its causes, signs and symptoms, pathogenesis.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.
Non-cystic Fibrosis Bronchiectasis (NCFB) Report Insights
Patient Population
Country-wise Epidemiology Distribution
Non-cystic Fibrosis Bronchiectasis (NCFB) Report Key Strengths
Ten-year Forecast
The 7MM Coverage
NCFB Epidemiology Segmentation
Non-cystic Fibrosis Bronchiectasis (NCFB) Report Assessment
Epidemiology Segmentation
Current Diagnostic Practices
FAQs
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of NCFB? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to NCFB
What is the historical and forecasted NCFB patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What is the diagnostic pattern of NCFB?
Which clinical factors will affect NCFB?
Which factors will affect the increase in the diagnosis of NCFB?
Reasons to buy
Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the change in NCFB cases in varying geographies over the coming years.
A detailed overview of total diagnosed prevalent cases, severity-specific cases, gender-specific cases, etiology-specific cases, and microbiology of NCFB patients is included.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
NCFB is a chronic lung condition marked by permanent bronchial dilation, leading to persistent sputum production, impaired bacterial clearance, and a cycle of infections, inflammation, and lung damage. Common symptoms include cough, sputum, and recurrent respiratory infections.
NCFB is frequently accompanied by comorbidities like anxiety, depression, and fatigue.
The causes of NCFB are varied, with many cases associated with idiopathic factors, post-infective causes, Chronic Obstructive Pulmonary Disease (COPD), asthma, and other conditions.
In 2024, there were approximately 1,050,000 diagnosed prevalent cases of NCFB in the 7MM.
Among the 7MM, the US accounted for approximately 37%, EU4 and the UK for nearly 54%, and Japan for around 9% of the total diagnosed prevalent cases of NCFB in 2024.
In 2024, females made up approximately 60% of diagnosed prevalent NCFB cases in the 7MM, while males accounted for around 40%.
DelveInsight’s “Non-cystic Fibrosis Bronchiectasis (NCFB) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of NCFB, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Non-cystic Fibrosis Bronchiectasis (NCFB): Disease Understanding
Non-cystic Fibrosis Bronchiectasis (NCFB) Overview, and Diagnosis
NCFB is a chronic respiratory condition involving irreversible bronchial dilation caused by airway injury, leading to inflammation, excess mucus production, and recurrent infections. NCFB, once under recognized and classified as an orphan respiratory disease, has become more prevalent globally, partly due to increased access to chest CT imaging.
Symptoms of NCFB range from occasional respiratory infections with excess mucus to chronic daily production of purulent sputum. Although not clearly defined, exacerbations typically involve increased sputum, worsening cough, wheezing, shortness of breath, hemoptysis, and declining lung function.
Diagnosis is primarily based on chest CT scans, though additional tests such as chest X-rays, bronchoscopy, pulmonary function tests, blood work, and sputum cultures may be conducted to detect underlying causes.
Non-cystic Fibrosis Bronchiectasis (NCFB) Epidemiology
The NCFB epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases, severity-specific diagnosed prevalent cases, gender-specific diagnosed prevalent cases, etiology-specific diagnosed prevalent cases, and microbiology of NCFB patients, in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.
In 2024, the total diagnosed prevalent cases of NCFB was approximately 388,000 in the US.
Among EU4 and the UK, the UK had the highest diagnosed prevalent population of NCFB, with nearly 229,500 cases in 2024, followed by Spain with approximately 152,200 cases. On the other hand, France had the lowest diagnosed prevalent population, with approximately 38,300 cases.
In 2024, there were approximately 90,000 mild, 160,000 moderate, and 138,000 severe cases of NCFB in the US.
In 2024, out of the diagnosed prevalent NCFB cases in US, ~105,000 were infected with P. aeruginosa, ~89,000 with H. influenzae, ~31,000 with S. pneumoniae, and ~78,000 with other pathogens, while no pathogenic growth was detected in ~85,000 cases.
In 2024, the gender-specific diagnosed prevalent cases of NCFB in the US were approximately 34% in males and 66% in females.
Scope of the Report
The report covers a segment of an executive summary, and a descriptive overview NCFB explaining its causes, signs and symptoms, pathogenesis.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.
Non-cystic Fibrosis Bronchiectasis (NCFB) Report Insights
Patient Population
Country-wise Epidemiology Distribution
Non-cystic Fibrosis Bronchiectasis (NCFB) Report Key Strengths
Ten-year Forecast
The 7MM Coverage
NCFB Epidemiology Segmentation
Non-cystic Fibrosis Bronchiectasis (NCFB) Report Assessment
Epidemiology Segmentation
Current Diagnostic Practices
FAQs
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of NCFB? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to NCFB
What is the historical and forecasted NCFB patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What is the diagnostic pattern of NCFB?
Which clinical factors will affect NCFB?
Which factors will affect the increase in the diagnosis of NCFB?
Reasons to buy
Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the change in NCFB cases in varying geographies over the coming years.
A detailed overview of total diagnosed prevalent cases, severity-specific cases, gender-specific cases, etiology-specific cases, and microbiology of NCFB patients is included.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Table of Contents
85 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Non-cystic Fibrosis Bronchiectasis (NCFB) Patient Overview at a Glance
- 3.1. Patient Share Distribution (%) in the 7MM in 2024
- 3.2. Patient Share Distribution (%) in the 7MM in 2034
- 4. Executive Summary of NCFB
- 5. Epidemiology Forecast Methodology
- 6. Disease Background and Overview
- 6.1. Introduction
- 6.2. Signs and Symptoms
- 6.3. Causes
- 6.4. Diagnosis and Differential Diagnosis
- 6.4.1. Diagnostic Algorithm
- 6.4.2. Differential Diagnosis
- 6.4.3. Diagnostic Guidelines
- 7. Epidemiology and Patient Population
- 7.1. Key Findings
- 7.2. Assumptions and Rationale
- 7.3. Total Diagnosed Prevalent Cases of NCFB in the 7MM
- 7.5. The United States
- 7.5.1. Total Diagnosed Prevalent Cases of NCFB in the US
- 7.5.2. Gender-specific Diagnosed Prevalent Cases of NCFB in the US
- 7.5.3. Severity-specific Diagnosed Prevalent Cases of NCFB in the US
- 7.5.4. Etiology-specific Diagnosed Prevalent Cases of NCFB in the US
- 7.5.5. Microbiology of NCFB Patients in the US
- 7.6. EU4 and the UK
- 7.6.1. Total Diagnosed Prevalent Cases of NCFB in EU4 and the UK
- 7.6.2. Gender-specific Diagnosed Prevalent Cases of NCFB in EU4 and the UK
- 7.6.3. Severity-specific Diagnosed Prevalent Cases of NCFB in EU4 and the UK
- 7.6.4. Etiology-specific Diagnosed Prevalent Cases of NCFB in EU4 and the UK
- 7.6.5. Microbiology of NCFB Patients in EU4 and the UK
- 7.7. Japan
- 7.7.1. Total Diagnosed Prevalent Cases of NCFB in Japan
- 7.7.2. Gender-specific Diagnosed Prevalent Cases of NCFB in Japan
- 7.7.3. Severity-specific Diagnosed Prevalent Cases of NCFB in Japan
- 7.7.4. Etiology-specific Diagnosed Prevalent Cases of NCFB in Japan
- 7.7.5. Microbiology of NCFB Patients in Japan
- 8. Appendix
- 8.1. Acronyms and Abbreviations
- 8.2. Bibliography
- 8.3. Report Methodology
- 9. DelveInsight Capabilities
- 10. Disclaimer
- 11. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
